1. Home
  2. ENTX vs KNDI Comparison

ENTX vs KNDI Comparison

Compare ENTX & KNDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • KNDI
  • Stock Information
  • Founded
  • ENTX 2010
  • KNDI 2002
  • Country
  • ENTX Israel
  • KNDI China
  • Employees
  • ENTX N/A
  • KNDI N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • KNDI Auto Manufacturing
  • Sector
  • ENTX Health Care
  • KNDI Consumer Discretionary
  • Exchange
  • ENTX Nasdaq
  • KNDI Nasdaq
  • Market Cap
  • ENTX 90.2M
  • KNDI 91.2M
  • IPO Year
  • ENTX 2018
  • KNDI N/A
  • Fundamental
  • Price
  • ENTX $2.38
  • KNDI $1.17
  • Analyst Decision
  • ENTX Strong Buy
  • KNDI
  • Analyst Count
  • ENTX 1
  • KNDI 0
  • Target Price
  • ENTX $10.00
  • KNDI N/A
  • AVG Volume (30 Days)
  • ENTX 93.1K
  • KNDI 115.2K
  • Earning Date
  • ENTX 03-07-2025
  • KNDI 03-13-2025
  • Dividend Yield
  • ENTX N/A
  • KNDI N/A
  • EPS Growth
  • ENTX N/A
  • KNDI N/A
  • EPS
  • ENTX N/A
  • KNDI N/A
  • Revenue
  • ENTX $99,000.00
  • KNDI $118,127,232.00
  • Revenue This Year
  • ENTX N/A
  • KNDI N/A
  • Revenue Next Year
  • ENTX N/A
  • KNDI N/A
  • P/E Ratio
  • ENTX N/A
  • KNDI N/A
  • Revenue Growth
  • ENTX 607.14
  • KNDI N/A
  • 52 Week Low
  • ENTX $0.82
  • KNDI $0.89
  • 52 Week High
  • ENTX $3.35
  • KNDI $2.98
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 52.12
  • KNDI 56.77
  • Support Level
  • ENTX $2.32
  • KNDI $1.06
  • Resistance Level
  • ENTX $2.62
  • KNDI $1.12
  • Average True Range (ATR)
  • ENTX 0.21
  • KNDI 0.06
  • MACD
  • ENTX -0.00
  • KNDI 0.00
  • Stochastic Oscillator
  • ENTX 61.29
  • KNDI 53.85

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About KNDI Kandi Technologies Group Inc

Kandi Technologies Group Inc is engaged in the development, production, and distribution of electric vehicle (EV) products, EV parts, and off-road vehicle products in the Chinese market. Other product offerings include all-terrain vehicles, go-karts, utility vehicles, battery packs, and other systems. It generates maximum revenue through off-road vehicles. The company generates the majority of its revenue from the United states along with other Countries, followed by China.

Share on Social Networks: